In November, there was a noticeable increase in short interest in Cellebrite DI Ltd. (NASDAQ: CLBT). As of November 15, 1,490,000 shares were shorted, up 5.7% from 1,410,000 shares as of October 31. Based on an average trading volume of 120,300 shares, the days-to-cover ratio is 12.4 days. Currently, 4.2% of the shares of the stock are being sold short.
Cellebrite DI (NASDAQ: CLBT) released its most recent quarterly earnings report on November 17. Compared to the $0.04 market-reported average analyst forecast of $0.03 per share, the company’s $0.01 quarterly earnings per share came up short. Cellebrite DI’s return on equity was -867.35 percent, while its net margin was 62.60%. The company’s revenue for the quarter was $71.68 million, as opposed to analysts’ predictions of $73 million. Stock market analysts predict that Cellebrite DI will generate $0.08 in earnings per share this year.
On Friday, NASDAQ: CLBT decreased $0.22 to $4.47 during regular trading hours, with 230,205 shares traded as opposed to its usual daily turnover of 101,274. Recent price swings for Cellebrite DI ranged from a low of $3.80 to a high of $8.83. The company’s 50-day and 200-day moving averages are $4.51 and $4.86, respectively. The stock has an $847.74 million market cap, a P.E. ratio of 5.45, a PEG ratio of 22.42, and a beta of 1.15.
Several research analysts have recently released reports on CLBT shares. On Cellebrite DI, Cowen maintained an “outperform” rating while lowering their price objective from $13.00 to $10.00 in a report released on Friday, August 12. William Blair reduced Cellebrite DI’s “outperform” rating to a “market perform” rating in a study made public on Friday, August 12. Bank of America lowered its price objective for Cellebrite DI from $6.50 to $6.00 and downgraded its recommendation to “neutral” in a research note that was made public on Friday, August 12. Needham & Company LLC raised their price objective on Cellebrite DI from $6.00 to $6.50 in a report on Thursday, August 11, and rated the stock as a “buy.”
Last but not least, in a research note released on Friday, August 12, Cowen decreased their “outperform” rating and their target price for Cellebrite DI from $13.00 to $10.00. Two research analysts rated the stock as a hold, compared to five who gave the company’s shares a buy rating. The company currently has a consensus buy recommendation and an average target price of $8.83, according to data from Bloomberg.com.
Influential investors recently bought and sold shares of the company. Mawer Investment Management Ltd. boosted its stake in Cellebrite DI during the first quarter by 144.1%. Mawer Investment Management Ltd. now owns 208,747 shares worth $1,336,000 after purchasing an additional 123,232 shares over the last three months. Crescent Park Management L.P. grew its stake in Cellebrite DI shares by 2.5% during the second quarter. Crescent Park Management L.P. now directly owns 601,537 shares worth $3,068,000 after acquiring an additional 14,633 shares in the last quarter. Greenhaven Road Investment Management L.P. grew its stake in Cellebrite DI by 69.7% during the first quarter. Greenhaven Road Investment Management L.P. now owns 2,000,000 shares of the company’s stock, valued at $12,800,000. We increased our share count by 821,364 over the most recent quarter. Josh Arnold Investment Consultant LLC made a fresh investment in Cellebrite DI shares during the first quarter for roughly $64,000. DGS Capital Management LLC made its final investment in the second quarter, contributing $64,000 to new ownership in Cellebrite DI. Institutional investors and hedge funds own 20.41% of the company’s shares.
Solutions for investigations permitted by law are developed by Cellebrite DI Ltd. Through the investigative lifecycle, users of its DI platform can collect, review, process, and manage digital data for legally recognized inquiries. Its remedies deal with many problems, including child exploitation, murder, counterterrorism, border security, sexual offenses, human trafficking, corporate security, intellectual property theft, and civil litigation.